Similar articles for PMID: 21371238

Year	Number of Results
2001	1
2002	1
2003	1
2004	6
2005	2
2006	9
2007	11
2008	7
2009	19
2010	16
2011	15
2012	18
2013	7
2014	3
2024	0

1

Pharmacogenetic screening: HLA-B(*) 5701 vs. CYP2B6 G516T.

Lin AW, Yam WC, Lam HY, To S, Chan D, Chan KC, Lee SS. Lin AW, et al. HIV Med. 2011 Apr;12(4):255-6. doi: 10.1111/j.1468-1293.2010.00870.x. HIV Med. 2011. PMID: 21371238 Free article. No abstract available.

2

The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons.

Tong K, He ML, Lin CK, Guo L, Kung HF, Sung JJ, Lee SS. Tong K, et al. Clin Infect Dis. 2006 Aug 15;43(4):541-2; author reply 542-4. doi: 10.1086/505984. Clin Infect Dis. 2006. PMID: 16838248 No abstract available.

3

CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.

Powers V, Ward J, Gompels M. Powers V, et al. HIV Med. 2009 Sep;10(8):520-3. doi: 10.1111/j.1468-1293.2009.00718.x. Epub 2009 May 21. HIV Med. 2009. PMID: 19486190 Free article.

4

Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Saitoh A, Fletcher CV, Brundage R, Alvero C, Fenton T, Hsia K, Spector SA. Saitoh A, et al. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):280-5. doi: 10.1097/QAI.0b013e318040b29e. J Acquir Immune Defic Syndr. 2007. PMID: 17356468 Clinical Trial.

5

Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.

Masebe TM, Bessong PO, Nwobegahay J, Ndip RN, Meyer D. Masebe TM, et al. Dis Markers. 2012;32(1):43-50. doi: 10.3233/DMA-2012-0859. Dis Markers. 2012. PMID: 22297601 Free PMC article.

6

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.

Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S. Ramachandran G, et al. Antimicrob Agents Chemother. 2009 Mar;53(3):863-8. doi: 10.1128/AAC.00899-08. Epub 2009 Jan 5. Antimicrob Agents Chemother. 2009. PMID: 19124658 Free PMC article.

7

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. Saitoh A, et al. AIDS. 2007 Oct 18;21(16):2191-9. doi: 10.1097/QAD.0b013e3282ef9695. AIDS. 2007. PMID: 18090046

8

Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T).

Usami O, Ashino Y, Komaki Y, Tomaki M, Irokawa T, Tamada T, Hayashida T, Teruya K, Hattori T. Usami O, et al. Int J STD AIDS. 2007 Aug;18(8):575-6. doi: 10.1258/095646207781439810. Int J STD AIDS. 2007. PMID: 17686225

9

Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.

Phillips E, Bartlett JA, Sanne I, Lederman MM, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal SA, Haas DW. Phillips E, et al. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55-7. doi: 10.1097/QAI.0b013e31827ca50f. J Acquir Immune Defic Syndr. 2013. PMID: 23328091 Free PMC article. Clinical Trial. No abstract available.

10

Absence of CYP2B6 promoter -82T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections.

He ML, Lin C, Tong K, Xu B, Sung JJ, Kung HF, Lee SS. He ML, et al. Eur J Clin Pharmacol. 2006 Jul;62(7):585-6. doi: 10.1007/s00228-006-0163-6. Epub 2006 Jun 13. Eur J Clin Pharmacol. 2006. PMID: 16770645 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year